Update of TNF-alpha antagonists and cardiovascular disease in rheumatoid arthritis.

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Tumor necrosis factor-alpha (TNF-alpha) antagonists were unexpectedly found to have no beneficial effects in moderate-to-severe heart failure in two large randomized clinical trials. In certain doses, the agents were found to be harmful. These results have important implications for rheumatoid arthritis (RA). Patients with the disease have an increased risk for developing cardiovascular co-morbidity, including heart failure. Because of the beneficial effect of the TNF-alpha antagonists in the management of RA, these agents have gained widespread use. Rheumatologists and other physicians who provide care for RA are thus likely to encounter candidates for anti-TNF-alpha therapy who have overt or subclinical heart failure. Although data are currently not sufficient to support evidence-based recommendations, it is possible to make reasonable suggestions to guide clinical practice.

Original languageEnglish (US)
Pages (from-to)395-399
Number of pages5
JournalCurrent rheumatology reports
Issue number5
StatePublished - Oct 2005

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Update of TNF-alpha antagonists and cardiovascular disease in rheumatoid arthritis.'. Together they form a unique fingerprint.

Cite this